BEAT-meso (ETOP 13-18)
Adding atezolizumab to bevacizumab-chemotherapy slowed progression but did not lengthen survival overall; it did help patients with non-epithelioid tumours.
OS primary endpoint not met in the whole population; PFS improved; OS and PFS benefit in non-epithelioid disease. Reinforces non-epithelioid histology as the subgroup most responsive to immunotherapy.
Setting
Advanced pleural mesothelioma, first line: bevacizumab + carboplatin-pemetrexed ± atezolizumab
Phase
Phase 3
Sponsor
ETOP
Registry
Headline result
OS not significantly improved overall; benefit in non-epithelioid subgroup.
Reported
2024
Enrolled
400
Replication
Consistent with CheckMate 743 and IND.227 histology subgroup findings.
Pages like this
not linked directly; found by shared links- TrialIND.227 / KEYNOTE-483
Shares Epithelioid vs sarcomatoid (biphasic) mesothelioma, Pemetrexed, Mesothelioma.
- TrialCheckMate 743
Shares Epithelioid vs sarcomatoid (biphasic) mesothelioma, Pemetrexed, Mesothelioma.
- TrialDREAM3R
Shares Pemetrexed, Mesothelioma.
- PairingHistology → first-line choice in mesothelioma
Shares Epithelioid vs sarcomatoid (biphasic) mesothelioma, Pemetrexed, Mesothelioma.
- TrialLUME-Meso
Shares Pemetrexed, Mesothelioma.
- TrialMAPS
Shares Pemetrexed, Mesothelioma.
- TrialSTELLAR
Shares Pemetrexed, Mesothelioma.
- PersonSolange Peters